TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MRVI Stock 12 Month Forecast
Average Price Target
$4.00
▲(23.08% Upside)
Based on 3 Wall Street analysts offering 12 month price targets for Maravai Lifesciences Holdings in the last 3 months. The average price target is $4.00 with a high forecast of $4.00 and a low forecast of $4.00. The average price target represents a 23.08% change from the last price of $3.25.
Wells Fargo Keeps Their Buy Rating on Maravai Lifesciences Holdings (MRVI)MRVI (Overweight) 2Q25 Recap: Encouraging Base Business Stability; New Mgmt Targeting Return to Profitability by 2H26
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
―
Hold
―
Reiterated
08/11/25
Maravai Lifesciences Holdings (MRVI) Gets a Hold from Guggenheim
Maravai LifeScience Holdings Inc. (MRVI) PT Lowered to $2.50 at UBSUBS analyst John Sourbeer lowered the price target on Maravai LifeScience Holdings Inc. (NASDAQ: MRVI) to $2.50 (from $8.00) while maintaining a Neutral rating.
Bank of America Securities Sticks to Their Buy Rating for Maravai Lifesciences Holdings (MRVI)We do not make changes to our model, but lower the PO to $8 (was $9) now based on a 29x (was 35x) FY26 EV/EBITDA due to peer group compression.
Wells Fargo Keeps Their Buy Rating on Maravai Lifesciences Holdings (MRVI)MRVI (Overweight) 2Q25 Recap: Encouraging Base Business Stability; New Mgmt Targeting Return to Profitability by 2H26
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
―
Hold
―
Reiterated
08/11/25
Maravai Lifesciences Holdings (MRVI) Gets a Hold from Guggenheim
Maravai LifeScience Holdings Inc. (MRVI) PT Lowered to $2.50 at UBSUBS analyst John Sourbeer lowered the price target on Maravai LifeScience Holdings Inc. (NASDAQ: MRVI) to $2.50 (from $8.00) while maintaining a Neutral rating.
Bank of America Securities Sticks to Their Buy Rating for Maravai Lifesciences Holdings (MRVI)We do not make changes to our model, but lower the PO to $8 (was $9) now based on a 29x (was 35x) FY26 EV/EBITDA due to peer group compression.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
trades and holding each position for 1 Month would result in 57.69% of your transactions generating a profit, with an average return of +2.00% per trade.
trades and holding each position for 3 Months would result in 47.06% of your transactions generating a profit, with an average return of -3.19% per trade.
Copying Daniel Arias's trades and holding each position for 1 Year would result in 41.18% of your transactions generating a profit, with an average return of -13.59% per trade.
trades and holding each position for 2 Years would result in 23.53% of your transactions generating a profit, with an average return of -39.84% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
MRVI Analyst Recommendation Trends
Rating
Aug 25
Sep 25
Oct 25
Nov 25
Dec 25
Strong Buy
6
3
3
1
0
Buy
5
3
3
4
5
Hold
18
10
9
6
6
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
29
16
15
11
11
In the current month, MRVI has received 5Buy Ratings, 6Hold Ratings, and 0Sell Ratings. MRVI average Analyst price target in the past 3 months is 4.00.
Each month's total comprises the sum of three months' worth of ratings.
MRVI Financial Forecast
MRVI Earnings Forecast
Next quarter’s earnings estimate for MRVI is -$0.07 with a range of -$0.10 to -$0.06. The previous quarter’s EPS was -$0.08. MRVI beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year MRVI has Performed in-line its overall industry.
Next quarter’s earnings estimate for MRVI is -$0.07 with a range of -$0.10 to -$0.06. The previous quarter’s EPS was -$0.08. MRVI beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year MRVI has Performed in-line its overall industry.
MRVI Sales Forecast
Next quarter’s sales forecast for MRVI is $49.02M with a range of $48.70M to $49.60M. The previous quarter’s sales results were $41.63M. MRVI beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year MRVI has Performed in-line its overall industry.
Next quarter’s sales forecast for MRVI is $49.02M with a range of $48.70M to $49.60M. The previous quarter’s sales results were $41.63M. MRVI beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year MRVI has Performed in-line its overall industry.
MRVI Stock Forecast FAQ
What is MRVI’s average 12-month price target, according to analysts?
Based on analyst ratings, Maravai Lifesciences Holdings, Inc.’s 12-month average price target is 4.00.
What is MRVI’s upside potential, based on the analysts’ average price target?
Maravai Lifesciences Holdings, Inc. has 23.08% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MRVI a Buy, Sell or Hold?
Maravai Lifesciences Holdings, Inc. has a consensus rating of Moderate Buy which is based on 2 buy ratings, 1 hold ratings and 0 sell ratings.
What is Maravai Lifesciences Holdings, Inc.’s price target?
The average price target for Maravai Lifesciences Holdings, Inc. is 4.00. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $4.00 ,the lowest forecast is $4.00. The average price target represents 23.08% Increase from the current price of $3.25.
What do analysts say about Maravai Lifesciences Holdings, Inc.?
Maravai Lifesciences Holdings, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.
How can I buy shares of MRVI?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.